The Fifth China Pharmaceutical Innovation and Investment Conference grandly opened in Suzhou
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2020-09-30
- Views:0
The Fifth China Pharmaceutical Innovation and Investment Conference grandly opened in Suzhou
News from the financial industry website Focusing on industrial policies, global pharmaceutical research and development trends, and investment and financing trends, the Fifth China Pharmaceutical Innovation and Investment Conference will be held in Suzhou Industrial Park from September 27 to 29, 2020. The conference was co-sponsored by the China Pharmaceutical Innovation Promotion Association, China Medical Device Industry Association, Hong Kong Stock Exchange, and Immeta Medical Consulting. The financial sector participated in the report as a strategic cooperative media.
At the opening ceremony of the conference, Ren Jinsheng, the annual chairman of China Pharmaceutical Innovation Promotion Association and chairman and CEO of Simcere Pharmaceutical, delivered a speech on behalf of the organizer. Ren Jinsheng said in his speech that the next five years will be a key opportunity period for the transformation and upgrading of China's biomedicine. China's pharmaceutical innovation and investment should not only pay attention to the internal circulation of market and resource elements, but also make good use of Chinese elements and China's advantages. , Vigorously promote foreign exchanges and cooperation, and use openness and cooperation to promote pharmaceutical innovation and investment.
Focused on the theme of the conference, and guests made wonderful sharing. Sha Yan, general manager of the Shenzhen Stock Exchange, said that the capital market will become a key booster for scientific and technological innovation in the biomedicine field, providing a source of power for accelerating the advancement of innovative technologies and the transformation of scientific and technological achievements in the biomedical field. In recent years, the Shenzhen Stock Exchange, especially the Growth Enterprise Market, has achieved remarkable results in cultivating and incubating biopharmaceutical companies and promoting the excellence and strength of the biopharmaceutical industry.
Elizabeth Myers, global chairman of JPMorgan Chase Investment Bank, gave a keynote speech through the cloud. She said that China's biomedical industry's strong demand for new products, technological advancement and government support have formed strong support, and biotechnology will be an important growth engine for China's medical and health industry.
Wang Yongjun, Dean of Beijing Tiantan Hospital, Capital Medical University, said that clinical big data and omics are a new method for drug research and development companies to find new drugs and new targets faster, and can effectively help the development of innovative drugs.
Zhang Yongxiang, chairman of the Chinese Pharmacological Society, shared the history and development trend of new drugs in my country. He said that important progress has been made in the major scientific and technological projects of the country's "Major New Drug Creation". At present, my country's new drug creation has entered a period of rapid development, and the prospects for new drug research and development and industrial development are very broad.
In addition, in the two thematic discussions on "Global Pharmaceutical Innovation Development Trends" and "Investment and Pharmaceutical Innovation", the chief medical officer of Rongchang Biotechnology, the chief scientist of SDIC Innovative Healthcare, and the former chief scientist of the Drug Evaluation Center of the State Food and Drug Administration He Ruyi believes that biological drugs and improved new drugs are two breakthrough points in the development of new drugs in line with China's actual conditions. Zhou Yunshu, chairman and general manager of Hengrui Pharmaceuticals, said that realizing the leap from imitation to innovation is a long and painful process. Long-term capital investment is the foundation of innovative activities. A high-level R&D team is the guarantee for innovative activities. The R&D technology platform is the core and key.
It is reported that the conference also set up nearly 20 exchange activities including the world premiere of clinical data, the special session for listed companies, the special session for non-listed companies, the special session for medical devices, the special session for science and technology innovation board, etc., for industry leaders, experts, scholars and domestic and foreign medical innovation Enterprises and investors build an authoritative, professional, multi-dimensional dialogue and communication platform
CONTACT INFORMATION
OFFICIAL ACCOUNTS
ONLINE MESSAGE
客户留言
Description: